Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | EIF4A1 | P60842 | 9/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204514 | 0.84 | KDM4E (0.50) | KDM4EMCHR1EIF4A1LMNAMAPT | |
| SCHEMBL6846654 | 0.79 | KMT2A (0.51) | KDM4EELANEALDH1A1LMNAMAPT | |
| SCHEMBL4659474 | 0.78 | ELANE (0.50) | ELANEALDH1A1HPGDKMT2A | |
| SCHEMBL28585527 | 0.78 | KDM4E (0.52) | KDM4EMCHR1ALDH1A1LMNAMAPT | |
| SCHEMBL28603449 | 0.78 | KDM4E (0.52) | KDM4EMCHR1ALDH1A1LMNAMAPT | |
| SCHEMBL6201951 | 0.78 | MCHR1 (0.47) | KDM4EMCHR1EIF4A1ALDH1A1MAPT | |
| SCHEMBL14127817 | 0.77 | KDM4E (0.55) | KDM4EMCHR1ALDH1A1LMNAMAPT | |
| SCHEMBL6596709 | 0.75 | ALDH1A1 (0.47) | ELANEALDH1A1MEN1KMT2A | |
| SCHEMBL1257817 | 0.75 | ELANE (0.72) | EIF4A1ELANEALDH1A1LMNAMAPT | |
| SCHEMBL2910393 | 0.74 | ALDH1A1 (0.67) | EIF4A1ELANEALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050009815-A1 | 4-Aminoquinoline compounds | DEVITA ROBERT J (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009815-A1 | 4-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | KDM4E 480/4885MCHR1 1/4885EIF4A1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.